Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Firstly the 13p was almost certainly a late reported trade from early in the day.
Secondly the market now appears to acknowledge Applied Graphene's technological base & multiple avenurs for market penetration & is prepared to price in the future.
Thirdly, even @ 30p, the market cap is only around some £15m & the company cash runway now extends to at least end 2021.
I think that the excitement is due to the funding being seen as the key to realising the potential of setrusumab for brittle bone disease.
Clearly those institutions & individuals participating in the funding have been convinced. Setrusumab could be a company maker.
The investee stock that is driving Arix NAV at the moment is Nasdaq lsted Imara. Launched on Nasdaq at $12.5 on 12th March & now on a steep upcurve. Closed yesterday at $52.25 = Market cap $900 = approx £70m to Arix.
Do not think that the market [ie the Arix share price] has taken this on board.
Bitcoin through $9500 as i write. Time, methinks, for the long awaited breakthrough & hold above $10000.
The world monetary system is near fatally compromised. Cometh the hour, cometh the altcoin.
And the BTC lift-off will power ARgo higher.
Sinden: Have you worked out what 1p is, in terms of market cap, on the new issued share capital? Caveat emptor.
Nice to know that Oxford Nanopore is working on a Covid-19 test - Nice to know that Firsyt Sentinal are invested in a company working on a Covid-19 vaccine.
And, every day, more announcements of disease tests - antibody tests - vaccines.
And big pharma tests will be priced for the "public good". So the whole thing will be sliced & diced & reduced to commodity pricing & so where will the profits be going forward?
Caveat emptor! These enormous price jumps on any Covid RNS are a trap. They will not be sustained.
Chester: Fully funded but only for a short time. This is a company that takes your cash & puts it through the shredder.
And of course a funding could have been better designed. If the company has such a bright future ??? So useless [or conniving?] board & useless advisers.
Sotn: I would not say that you are aloof but maybe something of a pedant. And what a boring old world if everyone was excpected to read every word of every RNS & understand the same. Consider also that it is quite often illuminating to read not only the lines but between the lines. Now i presume that gjbrandon is Gerard. He comes across as a very capable chap & is a major reason that many are invested here although i have some antipathy to referring to oneself in the third person.
As to director's dealings i suspect the important thing to look out for as the share rerates would be director's selling!
And yes, i am a long term holder just so long as the investment case, in my humble opinion, continues to stack up.
UserSteve: How do i quantify the potential? Well, water, as in safe potable water & waste water and waste products are the elephant in the room. Water is Free !! Just flush & all the nasty stuff goes away !!.
But water is not free. Both domestically & in industry we consume too much of, an often, finite resource. Ground water is the world's storage system & has to be replenished & REGULAR replenishment cannot be guaranteed. But potable water has to be safe. Reclaimed water for say agricultural use cannot be used without testing. A long running scandal of the developing world has been lack of safe drinking water & the diseases that flow from this [with huge economic costs].
Then there is the aphorism, "Knowledge is power", which we are now seeing played out. Waste water is an information source that can tell us so much, both looking backwards & forwards.
So, i believe that there will, inevitably, be a much increased focus, going forward, on water management, safe potable water & waste management and testing. The investment will be significant but with an enormous payback.
Modern water is in the right place at the right time. It just has to execute in order to succeed.
When i look at Modern Water now i see a company that has got its act together & is progressing on multiple fronts.
I then look at the market cap of £9m and ask myself; "Does this fully reflect the market potential of the company?" My answer [to myself] is; "No, it does not".
The focus right now is on Modern Water's testing sysyems for waste water & waste water products in connection with the current pandemic but the real value goes way beyond this. Identification of pathogens in waste water etc is an early warning system when time is of the utmost priority, both for existing infection rates & flare-up's in relation to Covid-19 and future novel pathogens.
In relation to pandemics knowledge is power & delay can have enormous negative implications. Just witness the UK failures & the exponential spread of the virus as a consequence.
And, so, my belief is that this type of testing will become standard in all developed geographies around the world & most of the developing also. The prize for Modern Water is there to be grasped. Success would, in time, result in a share price & market cap of multiples of where it stands at the present.
KAT up 22% pre market which values Kibo's 54.8% at £3.37M, ie not far short of current market cap.
RNS on Katoro this morning & well received. If this puts a rocket under Katoro then Kibo will be propelled higher.
SWNK: Can't say that your "facts" help particularly. But here are a couple more:
FACT: It will be dark tonight
FACT: It will be light again in the morning
So, Tim Buckley is the Chief Financial Officer [how many have they?]. As such he is the bean counter, not a scientist, not a strategist. So why has he got options over 4 million shares = 1.64% of share capital? These latest 2 million are excerciseable at 0.5p - Yes - half a penny. I have not checked what they actually pay him - what is laughably termed in PLC language as "compensation".
This is an interesting company but it is a small company & has been a serial underperformer. It has now got a lift from the Covid-19 pandemic. Did Mr Buckley have a hand in this? Was he patient zero?
Pigs and troughs are the words that come to mind.
Covid-19 is giving a lift to Lidco's sales but, more importantly is showcasing their hemodynamic monitoring technology internationally.
Lidco's aim has always been for their systems to be a fixture in ALL critical care settings in ALL geographies with advanced healthcare systems.
This is the tipping point for Lidco as a company. Not a "shooting star" but a steady appreciation in value.
The 4% holder appears to be a Spanish manufacturing company - The 9% holder is a UK value fund management company.
Clearly somthing has inspired this rush of buying. Maybe, in part the HC stock overhang has now cleared.
Another possibility is that they have received an approach re Skinny Tan which is, of course, the star in their firmanent. So the question that I ask myself is; "What is SK worth to a health & beauty consumer products company as a brand now established & to be built upon." As of yet I haven't answered my own question.
I am allergic to the fact that this excellent, early stage, drug discovery business is valued at peanuts.
I watched the proactive interview & was very encouraged. Active programmes number 6 or 7 and it is clear that there is novel science behind each & that each are intended to meet clinical needs for which there is large demand. IE: none of them are vanity projects.
Both the sickle-cell & psoriasis programmes look like major potential licensing opportunities, ie somewhere north in value of the Indivior deal.
Patience may be required but here, i suspect, patience will indeed be a virtue.
Strong results. This is a company that is quietly going about its business of drug discovery. Considerable potential to be realised imo. This is not a Covid-19 Icarus type stock that will fly too close to the sun & then crash to earth. More a buy & hold for steady appreciation. So "Hare & Tortoise" - and who won the race?
PI's who believe in the rationale & economic potential of this deal with use the pull back caused by stale holders exiting as an opportunity to add.